Terzin is recombinant human granulocyte colony-stimulating factor, which can promote the differentiation of infantile granulocytes in bone marrow to mature granulocytes, prompt the release of mature granulocytes from bone marrow, increase the number of granulocytes in peripheral blood, and thus enhance the immune function of human body. It is commonly used clinically in patients with various causes of granulocyte reduction or deficiency, such as patients with aplastic anemia, due to the failure of bone marrow hematopoietic function. The number of leukocytes in the peripheral blood decreases and the patient is prone to infections and fever, so Terzin can be used to increase the number of leukocytes in the peripheral blood, thus increasing the patient’s resistance. After chemotherapy, leukemia patients will experience severe myelosuppression, and the number of leukocytes in the peripheral blood decreases, and patients are prone to serious infections, so Tertin can also be used to increase the number of leukocytes in the peripheral blood to control infections. Other solid tumors, which may also show leukopenia after chemotherapy, can also be treated with Tertzin.